source
- Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, SanofiCorbus Pharmaceuticals’ phase 1b obesity trial has generated evidence its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The biote…Fierce Biotech · 5h ago↗ source
- Electra aims for $342M IPO to power inflammatory drug’s push through phase 3Electra Therapeutics is hoping to raise up to $341.9 million from an IPO in order to power the clinical development of its inflammatory disorder drug ipsoprubart.Fierce Biotech · 6h ago↗ source
- Analysis says secret Trump pharma deals could cut projected Medicare savings from MFN pricing by up to 80%A new analysis warns that confidential agreements between the Trump administration and more than two dozen drug makers could dramatically shrink the savings expected from the "most‑favored‑nation"…